TScan Therapeutics, Inc.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Mar 2022 | — | $145.7M | $140.8M |
| Jun 2022 | — | $131.7M | $125.6M |
| Sep 2022 | $29.1M | $116.7M | $137.3M |
| Dec 2022 | $29.3M | $99.4M | $120.0M |
| Mar 2023 | $29.5M | $78.0M | $95.6M |
| Jun 2023 | $29.7M | $190.6M | $208.8M |
| Sep 2023 | $28.8M | $169.0M | $155.2M |
| Dec 2023 | $26.7M | $150.9M | $133.4M |
| Mar 2024 | $23.4M | $123.0M | $140.5M |
| Jun 2024 | $20.1M | $255.2M | $242.2M |
| Sep 2024 | $30.6M | $229.1M | $133.1M |
| Dec 2024 | $32.1M | $241.0M | $178.7M |
| Mar 2025 | $32.2M | $210.2M | $154.1M |
| Jun 2025 | $32.3M | $176.7M | $169.4M |
| Sep 2025 | $32.4M | $144.0M | $169.5M |
| Dec 2025 | $32.5M | $123.1M | $152.4M |
| Mar 2026 | $32.7M | $96.9M | $128.1M |
| Jun 2026 | $21.1M | $69.0M | $100.2M |